Navigation Links
Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
Date:8/6/2008

Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, Aug. 6 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that it has entered into a definitive development, distribution and supply agreement with Ranbaxy Pharmaceuticals Inc. ("RPI"), a wholly owned subsidiary of Ranbaxy Laboratories Limited, under which Cipher has granted RPI the exclusive right to market, sell and distribute CIP-ISOTRETINOIN in the United States, its territories and possessions.

CIP-ISOTRETINOIN is a novel, patented formulation of isotretinoin, which is used in the treatment of severe nodular acne. The product received approvable letters from the U.S. Food and Drug Administration ("FDA") in May 2006 and April 2007 in which the FDA requested that Cipher provide additional clinical safety data. Cipher and its advisors are currently in discussions with the FDA's Division of Dermatology and Dental Products regarding the appropriate design of a safety study.

Under the terms of the agreement with RPI, Cipher received an initial upfront milestone payment of US$1 million. The agreement includes additional pre- and post-commercialization milestone payments of up to US$23 million, contingent upon the achievement of certain milestone targets. Once the product is successfully commercialized, Cipher will also receive a royalty in the mid-teens on net sales. In addition, RPI will reimburse Cipher for all costs associated with the clinical studies required to obtain FDA approval, up to a predetermined cap. Any additional development costs associated with initial FDA approval will be shared equally. Cipher is responsible for all product development activities, including management of the clinical studies required by the FDA to secure NDA approval. Cipher is also responsible for product supply and manufacturing, which would be fulfilled by its partner, Galephar Pharmaceutical Research. After product-related expenses are deducte
'/>"/>

SOURCE Cipher Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Ciphers revised NDA for CIP-TRAMADOL ER accepted for review by FDA
2. Cipher provides regulatory update for CIP-TRAMADOL ER
3. Cipher provides CIP-TRAMADOL ER regulatory update
4. Cipher appoints Stefan Aigner to board of directors
5. Cipher Appeals FDAs Decision On CIP-TRAMADOL ER
6. Cipher reports third quarter fiscal 2007 results
7. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
8. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
9. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
10. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... ... University of Pittsburgh Cancer Institute (UPCI) scientists recently led a ... available tests that better incorporate personalized medicine into diagnosing the condition. , Their ... published in the July issue of the scientific journal Thyroid . The ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... & Medical Spa industries, announces the return of its complimentary educational webinar ... of aesthetic medical business leaders creates success for their clients through targeted marketing, ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud to ... Graduate Teaching Award on behalf of the department of Family Practice. , “This award ... to be practicing in. The technology is changing so rapidly and we are also ...
(Date:7/6/2015)... ... July 06, 2015 , ... Cancer Hope Network (CHN) has ... medical professionals to chat with the CHN patient services team and connect with ... diagnosis is often the most traumatic experience of a person’s life,” said CHN ...
(Date:7/6/2015)... ... 2015 , ... MD Now, the leading and fastest-growing urgent care provider in ... center will serve residents and visitors in the Cutler Bay area, giving them convenient ... Florida location, the new facility will be the fourth to serve Miami-Dade County. Located ...
Breaking Medicine News(10 mins):Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3
... woke up as married men Sunday after a clutch ... weekend. ,The off-field antics of the so-called ... were as much the focus as their husbands and ... there was an almighty fixture pile-up for those celebrities, ...
... flu in more than a year has highlighted growing complacency ... the country, experts said Sunday . A 20-year-old man from ... H5N1 strain a week ago, the communist government said, and ... the virus since last month. ,The country's first ...
... born after embryo biopsy for preimplantation genetic diagnosis (PGD) ... born after artificial reproduction technologies (ART) without PGD. ... at risk of transmitting genetic diseases. Instead of carrying ... pregnancy, in vitro fertilisation (IVF) with intracytoplasmic sperm injection ...
... has found that waiting just two minutes to cut the ... boost as it reduces the risk of blood disorders . ... University in Hamilton, Canada, and involved more than 1,900 newborns. ... university, said that the results showed that as little as ...
... have identified potential chinks in the parasite that causes ... some 12 million people around the world . Their ... cases of leishmaniasis could be a boon for drug ... already slender. ,British-led scientists compared the genetic ...
... her parents and doctors in a perplex state when her weight ... to the normal baby growth chart Kaceys recordings were way beyond ... see her ballooning. I was scared, worried - because the weight ... it was like two, three pounds every week. And it was ...
Cached Medicine News:Health News:WAG Wedding Extravaganza for England Footballers 2Health News:Vietnam Bird Flu Death a Call for Action, Say Experts 2Health News:Vietnam Bird Flu Death a Call for Action, Say Experts 3Health News:Children Born After PGD as Healthy as Kids Born After ART 2Health News:2 Minute Delay in Cutting Cord can Give Babies a 'significant' Health Boost 2Health News:Gene Study Throws Up New Targets for Leishmaniasis 2Health News:Obese Infant Kacey Causes Concern 2
(Date:7/6/2015)... 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ... announced the appointment of Joann V. Lofgren ... Market Development, effective July 6, 2015. In this role, ... executing on the company,s market and product development strategy ... to welcome Joann to the OncoSec team and have ...
(Date:7/5/2015)... TOKYO , July 6, 2015 ... first international symposium on Medical-Engineering Collaboration "Medicine ... on July 10, 2015 in Tokyo, ... or its medical applied research will present their ... technology and a new industry produced with 8K ...
(Date:7/4/2015)... Adding SIR-Spheres® Y-90 resin ... metastatic colorectal cancer in the liver (mCRC) further ... Patients with unresectable metastatic colorectal cancer (mCRC) that ... greatest improvement in Progression-Free Survival (PFS) in the ... microspheres to a current first-line chemotherapy regimen, according ...
Breaking Medicine Technology:OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4
... MATEO, Calif., Feb. 28, 2011 Nile Therapeutics, Inc. ... the development of novel therapeutics for heart failure patients, ... MDT ) on the clinical development of ... failure and renal disease applications. "We are ...
... 2011 Hotspur Technologies announced today that Dr. ... clinical use of its Keeper™ Embolectomy Catheter.  The ... within arteries, while also incorporating the capability of ... The Keeper Catheter combines a compliant ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3Hotspur's Keeper Embolectomy Catheter Deployed for First Time 2
Round solid 15 mm wide lower plate. Open upper plate with inside diameter 12 mm. Serrated handle with locking thumb screw and polished finish....
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
The popular E2002 Utrata Capsulorhexis Forceps with fine angled sharp tips. Angled 12 mm shafts with an iris stop. Flat handle with dull finish....
Fine angled tips ideal for grasping delicate capsule. Angled 12 mm shafts with iris stop allows ease of movement in the anterior chamber. Flat handle with dull finish. Manufactured in titanium....
Medicine Products: